マーケットレポート詳細

ドラッグ・リポジショニング市場:2034年予測

Drug Repurposing Market (Disease Indication: Oncology, CNS Diseases, Neurodegenerative Diseases, and Others; and End-user: Hospitals & Clinics, Ambulatory Surgery Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版元:Transparency Market Research  出版元について
発行年:2024年6月
定価:Single User License $5795 Multi User License $8795 Corporate User License $11795
ご請求は円換算(お見積り日TTSレート)となります。
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
納品形態:PDF by Email
当調査レポートは英文 134ページになります。
商品コード:TMR287

お問い合わせは、アイコンをクリックしてご入力ください。別タブでフォームが開きます。

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

report_image

ドラッグ・リポジショニングの世界市場規模は2023年で289億ドル、2034年に478億ドル、市場の平均年成長率は4.7%にて増加する見込みです。

当レポートでは、ドラッグ・リポジショニングの市場予測-2034年、各種セグメント別市場分析(適応疾患別、アプローチタイプ別、国地域別、等)、パイプライン分析、主要製品/ブランド分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■ドラッグ・リポジショニングの世界市場予測2020-2034年
・市場規模(US$)

■適応疾患別、市場-2034年
・腫瘍
・中枢神経系疾患
・神経変性疾患
・その他(希少疾患など)
※(市場規模US$) 

■アプローチタイプ別、市場-2034年
・疾患中心アプローチ
・ターゲット中心アプローチ
・薬剤中心アプローチ
※(市場規模US$) 

■エンドユーザー別、市場-2034年
・病院、クリニック
・外来手術疾患
・その他(研究機関など)
※(市場規模US$) 

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス
パイプライン分析
主要製品/ブランド分析
主要な合併、買収

■ドラッグ・リポジショニングの主要企業プロフィール動向
Algernon Pharmaceuticals
Biovista Inc.
Celentyx Ltd.
ChemBio Discovery Inc.
Chord Therapeutics SA
Excelra
Fios Genomics Ltd.
Lantern Pharma Inc.
Novartis AG
Paradigm Biopharmaceuticals Limited
Predictive Oncology
Segue Therapeutics, LLC
Teva Pharmaceutical Industries Ltd.
(全134頁)

Table of Contents (英文詳細目次)

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Drug Repurposing Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Drug Repurposing Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Drug Repurposing Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Indication, 2020-2034
6.3.1. Oncology
6.3.2. CNS Diseases
6.3.3. Neurodegenerative Diseases
6.3.4. Others (Rare Disorders, etc.)
6.4. Market Attractiveness Analysis, by Disease Indication

7. Global Drug Repurposing Market Analysis and Forecast, by Approach Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Approach Type, 2020-2034
7.3.1. Disease-centric approach
7.3.2. Target-centric approach
7.3.3. Drug-centric approach
7.4. Market Attractiveness Analysis, by Approach Type

8. Global Drug Repurposing Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals & Clinics
8.3.2. Ambulatory Surgery Diseases
8.3.3. Others (Research Institutes, etc.)
8.4. Market Attractiveness Analysis, by End-user

9. Global Drug Repurposing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Drug Repurposing Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Indication, 2020-2034
10.3.1. Oncology
10.3.2. CNS Diseases
10.3.3. Neurodegenerative Diseases
10.3.4. Others (Rare Disorders, etc.)
10.4. Market Value Forecast, by Approach Type, 2020-2034
10.4.1. Disease-centric approach
10.4.2. Target-centric approach
10.4.3. Drug-centric approach
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals & Clinics
10.5.2. Ambulatory Surgery Diseases
10.5.3. Others (Research Institutes, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Disease Indication
10.7.2. By Approach Type
10.7.3. By End-user
10.7.4. By Country

11. Europe Drug Repurposing Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Indication, 2020-2034
11.3.1. Oncology
11.3.2. CNS Diseases
11.3.3. Neurodegenerative Diseases
11.3.4. Others (Rare Disorders, etc.)
11.4. Market Value Forecast, by Approach Type, 2020-2034
11.4.1. Disease-centric approach
11.4.2. Target-centric approach
11.4.3. Drug-centric approach
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals & Clinics
11.5.2. Ambulatory Surgery Diseases
11.5.3. Others (Research Institutes, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Disease Indication
11.7.2. By Approach Type
11.7.3. By End-user
11.7.4. By Country/Sub-region

12. Asia Pacific Drug Repurposing Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Indication, 2020-2034
12.3.1. Oncology
12.3.2. CNS Diseases
12.3.3. Neurodegenerative Diseases
12.3.4. Others (Rare Disorders, etc.)
12.4. Market Value Forecast, by Approach Type, 2020-2034
12.4.1. Disease-centric approach
12.4.2. Target-centric approach
12.4.3. Drug-centric approach
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals & Clinics
12.5.2. Ambulatory Surgery Diseases
12.5.3. Others (Research Institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Disease Indication
12.7.2. By Approach Type
12.7.3. By End-user
12.7.4. By Country/Sub-region

13. Latin America Drug Repurposing Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Indication, 2020-2034
13.3.1. Oncology
13.3.2. CNS Diseases
13.3.3. Neurodegenerative Diseases
13.3.4. Others (Rare Disorders, etc.)
13.4. Market Value Forecast, by Approach Type, 2020-2034
13.4.1. Disease-centric approach
13.4.2. Target-centric approach
13.4.3. Drug-centric approach
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals & Clinics
13.5.2. Ambulatory Surgery Diseases
13.5.3. Others (Research Institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Disease Indication
13.7.2. By Approach Type
13.7.3. By End-user
13.7.4. By Country/Sub-region

14. Middle East & Africa Drug Repurposing Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Disease Indication, 2020-2034
14.3.1. Oncology
14.3.2. CNS Diseases
14.3.3. Neurodegenerative Diseases
14.3.4. Others (Rare Disorders, etc.)
14.4. Market Value Forecast, by Approach Type, 2020-2034
14.4.1. Disease-centric approach
14.4.2. Target-centric approach
14.4.3. Drug-centric approach
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals & Clinics
14.5.2. Ambulatory Surgery Diseases
14.5.3. Others (Research Institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Disease Indication
14.7.2. By Approach Type
14.7.3. By End-user
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Algernon Pharmaceuticals
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Biovista Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Celentyx Ltd.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. ChemBio Discovery Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Chord Therapeutics SA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Excelra
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Fios Genomics Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Lantern Pharma Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Novartis AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Paradigm Biopharmaceuticals Limited
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Predictive Oncology
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Segue Therapeutics, LLC
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Teva Pharmaceutical Industries Ltd.
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview

List of Tables

Table 01: Global Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

Table 02: Global Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034

Table 03: Global Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 04: Global Drug Repurposing Market Size (US$ Bn) Forecast, by Region, 2020-2034

Table 05: North America Drug Repurposing Market Size (US$ Bn) Forecast, by Country, 2020-2034

Table 06: North America Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

Table 07: North America Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034

Table 08: North America Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 09: Europe Drug Repurposing Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 10: Europe Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

Table 11: Europe Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034

Table 12: Europe Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 13: Asia Pacific Drug Repurposing Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Asia Pacific Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

Table 15: Asia Pacific Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034

Table 16: Asia Pacific Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 17: Latin America Drug Repurposing Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 18: Latin America Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

Table 19: Latin America Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034

Table 20: Latin America Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 21: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

Table 23: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034

Table 24: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global Drug Repurposing Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global Drug Repurposing Market Revenue (US$ Bn), by Disease Indication, 2023

Figure 03: Global Drug Repurposing Market Value Share, by Disease Indication, 2023

Figure 04: Global Drug Repurposing Market Revenue (US$ Bn), by Approach Type, 2023

Figure 05: Global Drug Repurposing Market Value Share, by Approach Type, 2023

Figure 06: Global Drug Repurposing Market Revenue (US$ Bn), by End-user, 2023

Figure 07: Global Drug Repurposing Market Value Share, by End-user, 2023

Figure 08: Global Drug Repurposing Market Value Share, by Region, 2023

Figure 09: Global Drug Repurposing Market Value (US$ Bn) Forecast, 2020-2034

Figure 10: Global Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 11: Global Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034

Figure 12: Global Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034

Figure 13: Global Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034

Figure 14: Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034

Figure 15: Global Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034

Figure 16: Global Drug Repurposing Market Value Share Analysis, by Region, 2023 and 2034

Figure 17: Global Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034

Figure 18: North America Drug Repurposing Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 19: North America Drug Repurposing Market Attractiveness Analysis, by Country, 2024-2034

Figure 20: North America Drug Repurposing Market Value Share Analysis, by Country, 2023 and 2034

Figure 21: North America Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 22: North America Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034

Figure 23: North America Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034

Figure 24: North America Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034

Figure 25: North America Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034

Figure 26: North America Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034

Figure 27: Europe Drug Repurposing Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 28: Europe Drug Repurposing Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 29: Europe Drug Repurposing Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 30: Europe Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 31: Europe Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034

Figure 32: Europe Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034

Figure 33: Europe Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034

Figure 34: Europe Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034

Figure 35: Europe Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034

Figure 36: Asia Pacific Drug Repurposing Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 37: Asia Pacific Drug Repurposing Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 38: Asia Pacific Drug Repurposing Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 39: Asia Pacific Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 40: Asia Pacific Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034

Figure 41: Asia Pacific Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034

Figure 42: Asia Pacific Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034

Figure 43: Asia Pacific Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034

Figure 44: Asia Pacific Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034

Figure 45: Latin America Drug Repurposing Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 46: Latin America Drug Repurposing Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 47: Latin America Drug Repurposing Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 48: Latin America Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 49: Latin America Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034

Figure 50: Latin America Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034

Figure 51: Latin America Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034

Figure 52: Latin America Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034

Figure 53: Latin America Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034

Figure 54: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 55: Middle East & Africa Drug Repurposing Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 56: Middle East & Africa Drug Repurposing Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 57: Middle East & Africa Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 58: Middle East & Africa Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034

Figure 59: Middle East & Africa Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034

Figure 60: Middle East & Africa Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034

Figure 61: Middle East & Africa Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034

Figure 62: Middle East & Africa Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034

△ 一番上に戻る